KAHR’s proprietary technology, known as DSP (Dual Signaling Proteins), enables the construction of targeted biological drugs with two functional ends, which can simultaneously block and/or activate two reinforcing biological signals resulting in a synergistic outcome. This platform represents a new generation of ultra-active immunotherapeutic biological drugs rationally designed for the treatment of multiple cancer indications.
DSPs are dual siganaling proteins generated by fusion of the active extracellular domains of a TNF-SF ligand and a type-I membrane protein
KAHR’s DSP pipeline includes checkpoint fusion proteins that are highly differentiated from current cancer immunotherapeutics and have the potential to become the next-generation of cancer immunotherapy. Dual target activation, by the two functional sides of each DSP drug candidate, offers multiple functionalities that act simultaneously and result in a synergistic effect. For example, a DSP can block candidate checkpoint molecules in cancer cells while at the same time stimulating TNF superfamily costimulatory receptors on immune cells.
- The unique DSP composition ensures target activation and increased potency by assembling a high multimer protein structure which is essential for activation of the TNF receptor family
- The DSP can be modularly designed for selective tumor site or tumor microenvironment targeting
- The platform technology is adaptable to most checkpoint targets, ones that are already validated in human or ones that are currently in clinical development and thereby potentially improving efficacy while maintaining a favorable risk/benefit ratio